Actions at Non-CB1/CB2 Cannabinoid Receptors

  • Mary E. Abood
  • Roger G Sorensen
  • Nephi Stella

Part of the The Receptors book series (REC, volume 24)

Table of contents

  1. Front Matter
    Pages i-xi
  2. Overview of Non-Cannabinoid Receptors

    1. Front Matter
      Pages 1-1
    2. Grzegorz Godlewski, George Kunos
      Pages 3-27
    3. Evangelia Kotsikorou, Patricia Reggio
      Pages 29-51
  3. G Protein-Coupled Receptors

    1. Front Matter
      Pages 53-53
    2. Hui-Chen Lu, Jane E. Lauckner, John W. Huffman, Ken Mackie
      Pages 55-69
    3. Lauren S. Whyte, Ruth A. Ross
      Pages 71-113
    4. Clara Andradas, María M. Caffarel, Eduardo Pérez-Gómez, Manuel Guzmán, Cristina Sánchez
      Pages 115-133
    5. Neta Rimmerman, Ewa Kozela, Rivka Levy, Zvi Vogel, Ana Juknat
      Pages 143-171
  4. Ion Channels

    1. Front Matter
      Pages 173-173
  5. Transcription Factors

    1. Front Matter
      Pages 219-219
    2. James Burston, David Kendall
      Pages 221-233
    3. Paola Mascia, Gianluigi Tanda, Sevil Yasar, Stephen J. Heishman, Steven R. Goldberg
      Pages 235-260
  6. Conclusions/Therapeutic Potential

    1. Front Matter
      Pages 261-261
    2. Mary E. Abood, Roger G. Sorensen, Nephi Stella
      Pages 263-280
  7. Back Matter
    Pages 281-286

About this book


The cloning of two G protein-coupled cannabinoid receptors, termed CB1 and CB2, in the early 1990s has stimulated and facilitated research conducted on the physiological function of cannabinoid actions in the brain and throughout the body. In the twenty years since the identification of these two receptors, endogenous ligands (endocannabinoids) for these receptors have been identified, their biosynthetic and metabolic pathways have been discerned, and their functional and regulatory action for signalling through CB1 and CB2 receptors have been described. More recently, it has become has become evident that cannabinoids exert actions at non-CB1, non-CB2 receptors. Much less is understood about these actions. Many of these novel “targets” are in the process of being characterized functionally and physiologically, and the therapeutic value of targeting these non-CB1, non-CB2 receptors is being evaluated. The purpose of this volume is to present the current knowledge on the atypical actions of cannabinoids on these new targets.


This book is intended as a scientific resource for cannabinoid researchers carrying out animal and human experiments, and for those who are interested in learning about future directions in cannabinoid research. Additionally, this book may be of value to investigators currently working outside the field of cannabinoid research who have an interest in learning about these compounds and their atypical cannabinoid signalling. This book provides insight into the potential medical application of cannabinoids and their therapeutic development for the treatment of human disease.


animal research atypical endocannabinoid actions atypical endocannabinoid receptors cannabinoids endocannabinoids human research neuroscience physiological function

Editors and affiliations

  • Mary E. Abood
    • 1
  • Roger G Sorensen
    • 2
  • Nephi Stella
    • 3
  1. 1., Anatomy and Cell BiologyTemple University School of MedicinePhiladelphiaUSA
  2. 2.National Institutes of Health, Division of Basic Neuroscience and BehavNational Institute on Drug AbuseBethesdaUSA
  3. 3., Pharmacology and Psychiatry and BehaviorUniversity of WashingtonSeattleUSA

Bibliographic information